Long-Term Open-Trial of Mizoribine with Prednisolone in 24 Patients with Multiple Sclerosis. Safety, Clinical and Magnetic Resonance Imaging Outcome.
-
- SAIDA Kyoko
- The Department of Neurology, Nishinara National Hospital
-
- ZHIGANG Zhao
- The Department of Neurology, Utano National Hospital
-
- OZAWA Kyoko
- The Department of Neurology, Utano National Hospital
-
- KONISHI Tetsuro
- The Department of Neurology, Utano National Hospital
-
- SAIDA Takahiko
- The Department of Neurology, Utano National Hospital
この論文をさがす
抄録
Object Mizoribine (MZR), imidazole nucleotide, inhibits purine synthesis and helper T cell functions. It is used as an immunosuppressant in chronic rheumatic arthritis in Japan. Twenty-four patients with relapsing-remitting and chronic progressive multiple sclerosis (MS) were studied for the long-term effects of MZR over 8 years. Methods Average daily MZR doses of 200 mg along with prednisolone (PSL) were administered in the patients studied. Ten of 24 patients were treated for more than 5 years. Results The mean relapse rate per year at entry (1.50±0.24, mean±SE, n=22) decreased [0.46±0.24 (n=19)] after two years. In 70% of the patients, the disability did not worsen. Eleven of 18 patients showed a mild decrease of the total lesion size in magnetic resonance imaging (MRI). Conclusion MZR was well tolerated and could be used for long-term in MS as an adjunctive immunosuppressant to PSL, and the PSL doses could be decreased. A further randomized controlled trial with PSL is necessary.<br>(Internal Medicine 38: 636-642, 1999)
収録刊行物
-
- Internal Medicine
-
Internal Medicine 38 (8), 636-642, 1999
一般社団法人 日本内科学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679843882752
-
- NII論文ID
- 10005529781
-
- NII書誌ID
- AA10827774
-
- COI
- 1:CAS:528:DyaK1MXmsVGjsro%3D
-
- ISSN
- 13497235
- 09182918
-
- NDL書誌ID
- 4806309
-
- PubMed
- 10440499
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可